000126810 001__ 126810
000126810 005__ 20240228140848.0
000126810 0247_ $$2doi$$a10.1016/S1470-2045(14)70412-7
000126810 0247_ $$2pmid$$apmid:25638685
000126810 0247_ $$2ISSN$$a1470-2045
000126810 0247_ $$2ISSN$$a1474-5488
000126810 0247_ $$2altmetric$$aaltmetric:3222327
000126810 037__ $$aDKFZ-2017-02838
000126810 041__ $$aeng
000126810 082__ $$a610
000126810 1001_ $$aKamada, Tadashi$$b0
000126810 245__ $$aCarbon ion radiotherapy in Japan: an assessment of 20 years of clinical experience.
000126810 260__ $$aLondon$$bThe Lancet Publ. Group$$c2015
000126810 3367_ $$2DRIVER$$aarticle
000126810 3367_ $$2DataCite$$aOutput Types/Journal article
000126810 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1522242348_30780
000126810 3367_ $$2BibTeX$$aARTICLE
000126810 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000126810 3367_ $$00$$2EndNote$$aJournal Article
000126810 520__ $$aCharged particle therapy is generally regarded as cutting-edge technology in oncology. Many proton therapy centres are active in the USA, Europe, and Asia, but only a few centres use heavy ions, even though these ions are much more effective than x-rays owing to the special radiobiological properties of densely ionising radiation. The National Institute of Radiological Sciences (NIRS) Chiba, Japan, has been treating cancer with high-energy carbon ions since 1994. So far, more than 8000 patients have had this treatment at NIRS, and the centre thus has by far the greatest experience in carbon ion treatment worldwide. A panel of radiation oncologists, radiobiologists, and medical physicists from the USA and Europe recently completed peer review of the carbon ion therapy at NIRS. The review panel had access to the latest developments in treatment planning and beam delivery and to all updated clinical data produced at NIRS. A detailed comparison with the most advanced results obtained with x-rays or protons in Europe and the USA was then possible. In addition to those tumours for which carbon ions are known to produce excellent results, such as bone and soft-tissue sarcoma of the skull base, head and neck, and pelvis, promising data were obtained for other tumours, such as locally recurrent rectal cancer and pancreatic cancer. The most serious impediment to the worldwide spread of heavy ion therapy centres is the high initial capital cost. The 20 years of clinical experience at NIRS can help guide strategic decisions on the design and construction of new heavy ion therapy centres.
000126810 536__ $$0G:(DE-HGF)POF3-315$$a315 - Imaging and radiooncology (POF3-315)$$cPOF3-315$$fPOF III$$x0
000126810 588__ $$aDataset connected to CrossRef, PubMed,
000126810 650_7 $$07440-44-0$$2NLM Chemicals$$aCarbon
000126810 7001_ $$aTsujii, Hirohiko$$b1
000126810 7001_ $$aBlakely, Eleanor A$$b2
000126810 7001_ $$0P:(DE-He78)8714da4e45acfa36ce87c291443a9218$$aDebus, Jürgen$$b3$$udkfz
000126810 7001_ $$aDe Neve, Wilfried$$b4
000126810 7001_ $$aDurante, Marco$$b5
000126810 7001_ $$0P:(DE-He78)440a3f62ea9ea5c63375308976fc4c44$$aJäkel, Oliver$$b6$$udkfz
000126810 7001_ $$aMayer, Ramona$$b7
000126810 7001_ $$aOrecchia, Roberto$$b8
000126810 7001_ $$aPötter, Richard$$b9
000126810 7001_ $$aVatnitsky, Stanislav$$b10
000126810 7001_ $$aChu, William T$$b11
000126810 773__ $$0PERI:(DE-600)2035574-9$$a10.1016/S1470-2045(14)70412-7$$gVol. 16, no. 2, p. e93 - e100$$n2$$pe93 - e100$$tThe @lancet <London> / Oncology$$v16$$x1470-2045$$y2015
000126810 909CO $$ooai:inrepo02.dkfz.de:126810$$pVDB
000126810 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)8714da4e45acfa36ce87c291443a9218$$aDeutsches Krebsforschungszentrum$$b3$$kDKFZ
000126810 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)440a3f62ea9ea5c63375308976fc4c44$$aDeutsches Krebsforschungszentrum$$b6$$kDKFZ
000126810 9131_ $$0G:(DE-HGF)POF3-315$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vImaging and radiooncology$$x0
000126810 9141_ $$y2015
000126810 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000126810 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000126810 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database
000126810 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bLANCET ONCOL : 2015
000126810 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search
000126810 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC
000126810 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bThomson Reuters Master Journal List
000126810 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000126810 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000126810 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine
000126810 915__ $$0StatID:(DE-HGF)9925$$2StatID$$aIF >= 25$$bLANCET ONCOL : 2015
000126810 9201_ $$0I:(DE-He78)E050-20160331$$kE050$$lKKE Strahlentherapie$$x0
000126810 9201_ $$0I:(DE-He78)E040-20160331$$kE040$$lMedizinische Physik in der Strahlentherapie$$x1
000126810 980__ $$ajournal
000126810 980__ $$aVDB
000126810 980__ $$aI:(DE-He78)E050-20160331
000126810 980__ $$aI:(DE-He78)E040-20160331
000126810 980__ $$aUNRESTRICTED